NAVER D2SF Makes Strategic Investment in AI-Driven Precision Medicine Venture ImpriMed

NAVER D2SF Strengthens Healthcare Investment with ImpriMed

NAVER D2SF, the corporate venture arm of NAVER, has recently made a significant investment in ImpriMed, a cutting-edge precision medicine company based in Silicon Valley. This investment, part of ImpriMed's $10 million Series A2 bridge round, aims to advance the capabilities of personalized cancer treatment.

ImpriMed leverages artificial intelligence-driven solutions to integrate ex vivo functional testing alongside genomic, immunophenotypic, and clinical data, streamlining the decision-making process for tailored cancer therapies. As precision oncology becomes increasingly reliant on sophisticated data integration, ImpriMed's innovative approach stands out by applying multimodal AI insights to provide more accurate treatment recommendations for patients with various cancer profiles.

At the heart of ImpriMed's offerings lies the xCellSense® platform, which is designed to maintain patient-derived live cancer cells in viable conditions ex vivo for extended durations. This allows for a comprehensive evaluation of their biological characteristics and drug sensitivities. By combining these insights with crucial data points from clinical practice, ImpriMed seeks to enhance treatment decisions significantly.

The company boasts an impressive dataset, having trained AI models on over 3.5 million data points that harness real-world data fused with functional analysis of cancer cells. Currently, ImpriMed is gearing up to launch products specifically targeting blood-related malignancies and infections. They anticipate receiving FDA clearance and CLIA certification by the first quarter of 2027 to initiate their U.S. market entry. Already, strong partnerships have been forged with major U.S. hospitals to pave the way for their healthcare solutions in North America.

In South Korea, ImpriMed has successfully developed software that assists in prognosis and therapy response predictions for multiple myeloma. This technological advancement has gained designation as an Innovative Medical Device from the Ministry of Food and Drug Safety (MFDS), further bolstering ImpriMed's presence in the healthcare market. Collaborative efforts are underway with top-tier tertiary hospitals, including the Catholic University Seoul St. Mary's Hospital and the Seoul Asan Medical Center, to refine their solutions in the region.

ImpriMed's strategy blends its experience in veterinary oncology with its human healthcare growth. Having conducted over 27,000 tests for dogs and cats with lymphoma, ImpriMed’s data reflects significant increases in treatment efficacy, demonstrating a threefold enhancement in survival rates. These findings have been substantiated through peer-reviewed publications, showcasing the company’s commitment to rigorous scientific standards.

Co-founded in Silicon Valley by CEO Sungwon Lim and CTO Jamin Koo, both of whom are KAIST and Stanford University alumni, ImpriMed combines talents from various fields including biomedical research, clinical collaboration, and AI modeling. With aspirations to extend their market reach beyond North America, they are eyeing expansions into Europe and Asia.

This $10 million investment round follows ImpriMed's previous $23 million Series A in 2023, led by LB Investment. Besides NAVER D2SF, notable participation came from Samsung Securities and Alois Ventures among existing backers like BonAngels and Han River Partners.

With NAVER D2SF's strategic investment, the firm continues to enhance its portfolio within the healthcare sector, aiming to support startups focused on the North American marketplace. This is facilitated through their founder network where other portfolio companies collaborate and share insights to optimize research and development as well as market strategies.

As NAVER D2SF continues its endeavors in healthcare innovations, their partnership with ImpriMed marks an exciting venture into the future of precision medicine, promising to reshape the landscape of personalized cancer therapies.